

RECEIVED
CENTRAL FAX CENTER

021/027

APR 24 2006

VPI/00-129-1 DIV US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Kahsay Habte Ph.D
Group Art Unit: 1624
Applicant: Robert Davies, et al.
Serial No.: 10/692,395 *35 M*
Confirmation No.: 8543
Filing Date: October, 23, 2003
For: PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE
INHIBITORS

Cambridge, Massachusetts
April 24, 2006

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PETITION PURSUANT TO 37 C.F.R. § 1.137(b)
FOR REVIVAL OF ABANDONED APPLICATION

Sir:

Pursuant to 37 C.F.R. § 1.137(b), applicants hereby petition for revival of the
above-identified patent application.

This application unintentionally became abandoned as of December 24, 2004
because of applicants' lack of response to the Office Action dated September 24, 2004,
which set a three-month period for response, extendable by three months.

As required by 37 C.F.R. § 1.137(b), this petition is accompanied by:

- (1) A reply to the Office Action; and
- (2) A authorization to charge deposit account in the amount of

\$1,500.00 in payment of the petition fee set forth in 37 C.F.R. § 1.17(m).

Pursuant to 37 C.F.R. §§ 1.137(c) and (d), this petition is not being accompanying by a terminal disclaimer. This is a utility application that was filed after June 8, 1995. Thus, no terminal disclaimer should be required in connection with this petition.

The entire delay in filing the required Office Action response, from the December 24, 2004 due date until the filing of this grantable petition under 37 C.F.R. § 1.137(b), was unintentional. Accordingly, applicants respectfully request that this petition be granted and the above-identified patent application be revived. Early and favorable consideration of this Petition is respectfully requested.

The Director is hereby authorized to charge any additional fee due, or credit any overpayment, in connection with this petition, to Deposit Account No. 50-0725. A duplicate copy of this Petition is enclosed herewith.

Respectfully submitted,



Jennifer G. Che (Reg. No. 58,035)
Agent for Applicants
Lisa A. Dixon (Reg. No. 40,995)
Attorney for Applicants
VERTEX PHARMACEUTICALS INCORPORATED
130 Waverly Street
Cambridge, Massachusetts 02139
Telephone: (617) 444-6525
Facsimile: (617) 444-6483

APR 24 2006

VPI/00-129-1 DIV US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Kahsay Habte Ph.D
Group Art Unit: 1624
Applicant: Robert Davies, et al.
Serial No.: 10/692,333 *355 Pf*
Confirmation No.: 8543
Filing Date: October, 23, 2003
For: PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE
INHIBITORS

Cambridge, Massachusetts
April 24, 2006

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PETITION PURSUANT TO 37 C.F.R. § 1.137(b)
FOR REVIVAL OF ABANDONED APPLICATION

Sir:

Pursuant to 37 C.F.R. § 1.137(b), applicants hereby petition for revival of the above-identified patent application.

This application unintentionally became abandoned as of December 24, 2004 because of applicants' lack of response to the Office Action dated September 24, 2004, which set a three-month period for response, extendable by three months.

As required by 37 C.F.R. § 1.137(b), this petition is accompanied by:

- (1) A reply to the Office Action; and
- (2) A authorization to charge deposit account in the amount of


\$1,500.00 in payment of the petition fee set forth in 37 C.F.R. § 1.17(m).

Pursuant to 37 C.F.R. §§ 1.137(c) and (d), this petition is not being accompanying by a terminal disclaimer. This is a utility application that was filed after June 8, 1995. Thus, no terminal disclaimer should be required in connection with this petition.

The entire delay in filing the required Office Action response, from the December 24, 2004 due date until the filing of this grantable petition under 37 C.F.R. § 1.137(b), was unintentional. Accordingly, applicants respectfully request that this petition be granted and the above-identified patent application be revived. Early and favorable consideration of this Petition is respectfully requested.

The Director is hereby authorized to charge any additional fee due, or credit any overpayment, in connection with this petition, to Deposit Account No. 50-0725. A duplicate copy of this Petition is enclosed herewith.

Respectfully submitted,



Jennifer C. Che (Reg. No. 58,035)
Agent for Applicants
Lisa A. Dixon (Reg. No. 40,995)
Attorney for Applicants
VERTEX PHARMACEUTICALS INCORPORATED
130 Waverly Street
Cambridge, Massachusetts 02139
Telephone: (617) 444-6525
Facsimile: (617) 444-6483